In one cohort, non-small cell lung cancer patients carrying low-function CYP2D6 genotypes had a significantly increased risk of ≥Grade 2 rash during gefitinib therapy compared to those with normal CYP2D6 activity [22]. The gene discussed is CYP2D6; the disease is non-small cell lung carcinoma.